GET DAILY SIGNALSAbbott (ABT) Delivers Q3 2026 Results With +9.2% EPS Growth and Nutrition Spin-Off Plans
Key Takeaways
- Abbott reported adjusted earnings per share (EPS) of $1.42, up 9.2% from $1.30 a year ago and slightly below the consensus estimate of $1.43.
- Revenue rose 14.5% on a reported basis to $13.01 billion, with comparable (organic) sales growth of 7.0%, led by double-digit gains in Electrophysiology and Rhythm Management.
- Abbott tightened its full-year 2026 adjusted EPS guidance to $5.50–$5.55 but lowered its comparable sales growth outlook to approximately 6.0%, down from 6.5%–7.5%.
- The company announced plans to spin off its Nutrition business into a separate, publicly traded company by the end of 2027.
- Shares fell roughly 3.6% in pre-market trading, with the lowered sales outlook and restructuring announcement weighing on sentiment.
Earnings Context and Why It Matters
Abbott Laboratories is a diversified healthcare company spanning medical devices, diagnostics, established pharmaceuticals, and nutrition. Its third-quarter 2026 results matter because they show whether management can sustain an acceleration in both top- and bottom-line growth after a comparatively slower first half. The quarter was also shaped by two major developments: the March 2026 acquisition of Exact Sciences, which transformed the Diagnostics segment, and the newly announced plan to separate the Nutrition business. Investors are closely watching whether core franchises such as diabetes care and electrophysiology can keep growing while the company reshapes its portfolio and margins. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, Abbott reported net sales of $13.01 billion, up 14.5% on a reported basis and 7.0% on a comparable basis from $11.37 billion a year earlier. Adjusted diluted EPS came in at $1.42, compared with $1.30 in the prior-year period. On a generally accepted accounting principles (GAAP) basis, diluted EPS from continuing operations was $0.53, down from $0.94 a year ago, reflecting the impact of specified items.
Across segments, Medical Devices sales rose 6.9% on a reported basis to $5.83 billion (7.8% comparable), with Electrophysiology up 15.5% and Rhythm Management up 10%. Diagnostics surged 46.7% on a reported basis to $3.31 billion, boosted by Exact Sciences, while comparable growth was 6.4%. Established Pharmaceuticals grew 6.8% to $1.61 billion (8.4% comparable), and Nutrition rose 5.1% to $2.26 billion (4.9% comparable), led by an 8.7% increase in Pediatric Nutrition. From what I see, the segment details highlight steady underlying momentum despite the headline acquisition boost.
Market Reaction and Investor Sentiment
Shares of ABT slipped about 3.6% in pre-market trading after the release, as investors weighed a mixed quarter against the strategic news. The slight EPS miss versus consensus and the reduction in full-year comparable sales growth guidance were the main drags on sentiment, even though revenue edged past estimates and profitability improved. The expanded adjusted gross margin of 57.2%, up roughly 143 basis points (bps) year over year, was a bright spot. The announcement of the Nutrition spin-off added a layer of uncertainty, with investors assessing both the long-term benefits of a more focused portfolio and the near-term execution risks.
Forward Outlook and Key Factors to Monitor
Abbott tightened its full-year 2026 adjusted EPS guidance to a range of $5.50 to $5.55, reaffirming the midpoint of its previous range. However, management now projects comparable sales growth of approximately 6.0% for the year, down from a prior range of 6.5% to 7.5%. For the fourth quarter, Abbott guided to adjusted EPS of $1.62 to $1.67.
Investors should monitor several factors going forward. First, the planned separation of the Nutrition business — which generates roughly $8.5 billion in annual revenue through brands such as Similac, Ensure, and Pedialyte — will reshape Abbott's growth profile and is expected to improve overall sales growth and operating margins over time. Second, the pace of adoption of new devices, including the Volt pulsed-field ablation (PFA) catheter in Electrophysiology and the newly approved Libre Duo glucose-ketone sensor in Diabetes Care, will be key demand signals.
Finally, watch margin trends and cost discipline, as well as the continued integration of Exact Sciences within Diagnostics. Foreign exchange is also expected to have a roughly 1% negative impact on fourth-quarter sales. These elements will help determine whether Abbott's growth acceleration can be sustained into 2027. One thing that stands out is how the spin-off could streamline focus on higher-growth areas.
Using AI Tools in My Research Process
In my analysis of earnings reports like this one, I often turn to Tickeron’s AI Screener for quick comparisons across healthcare peers. It helps filter by fundamentals, technical signals, and industry trends, giving me a clearer picture of relative performance without spending hours on manual screens. This approach keeps my workflow efficient when evaluating quarterly updates and guidance changes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ABT in +2.49% Uptrend, growing for three consecutive days on October 16, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ABT advanced for three days, in 172 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ABT's RSI Oscillator exited the oversold zone, 16 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 43%.
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on ABT as a result. In 46 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 53%.
The Moving Average Convergence Divergence (MACD) for ABT just turned positive on October 09, 2026. Looking at past instances where ABT's MACD turned positive, the stock continued to rise in 25 of 54 cases over the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for ABT crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 5 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 42%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
ABT broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ABT entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. ABT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.469) is normal, around the industry mean (2.979). P/E Ratio (33.048) is within average values for comparable stocks, (2.590). Projected Growth (PEG Ratio) (1.853) is also within normal values, averaging (11.052). Dividend Yield (0.025) settles around the average of (0.009) among similar stocks. P/S Ratio (3.836) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of health care products
Industry MedicalNursingServices
Advertisement